Mechanisms responsible for poor oral bioavailability of paeoniflorin: Role of intestinal disposition and interactions with sinomenine

Pharmaceutical Research

Volumn 23, Issue 12, 2006, Pages 2768-2780

  Liu, Zhong Qiu ^a,b   Jiang, Zhi Hong ^b   Liu, Liang ^b   Hu, Ming ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Bioavailability; Caco 2; Disposition; Efflux; Intestinal; p glycoprotein inhibitor; Paeoniflorin; Sinomenine

Indexed keywords

ABC TRANSPORTER; AGLYCONE; BENZOIC ACID; CYCLOSPORIN A; DIGOXIN; DRUG METABOLITE; ENZYME INHIBITOR; GLUCONOLACTONE; GLUCOSIDASE; GLUCOSIDASE INHIBITOR; GLUCOSIDE; GLYCOPROTEIN P; LACTONE DERIVATIVE; LEUKOTRIENE C4; MULTIDRUG RESISTANCE PROTEIN; PAEONIFLORIGENIN; PAEONIFLORIN; SINOMENINE; VERAPAMIL; VERLUKAST;

ANIMAL CELL; ARTICLE; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; DUODENUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE PERFUSION; JEJUNUM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATP-BINDING CASSETTE TRANSPORTERS; BENZOIC ACIDS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BRIDGED COMPOUNDS; CACO-2 CELLS; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIGOXIN; DRUG INTERACTIONS; GLUCOSIDES; HUMANS; INTESTINAL ABSORPTION; MALE; MORPHINANS; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33845350626     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9100-8     Document Type: Article

References (30)

1. J. Yamahara, T. Yamada, H. Kimura, T. Sawada, and H. Fujimura. Biologically active principles of crude drug. II. Anti-allergic principles in "Shoseir-yu-To" anti-inflammatory properties of paeoniflorin and its derivatives. J. Pharmacobio-Dyn. 5:921-929 (1982).
2. M. Kimura, I. Kimura, and H. Nojima. Depolarizing neuromuscular blocking action induced by electropharmacological coupling in the combined effect of paeoniflorin and glycyrrhizin. Jpn. J. Pharmcol. 37:395-397 (1984).
3. S. Takeda, T. Isono, Y. Wakui, Y. Matsuzaki, H. Sasaki, and S. Amagaya. Absorption and excretion of paeoniflorin in rats. J. Pharm. Pharmacol. 47:1036-1040 (1995).
4. S. Takeda, T. Isono, Y. Wakui, Y. Mizuhara, S. Amagaya, M. Maruno, and M. Hattori. In-vivo assessment of extrahepatic metabolism of paeoniflorin in rats: relevance to intestinal floral metabolism. J. Pharm. Pharmacol. 49:35-39 (1997).
5. Z. Q. Liu, H. Zhou, L. Liu, Z. H. Jiang, Y. F. Wong, Y. Xie, X. Cai, H. X. Xu, and K. C. Chan. The pharmacokinetic fate of paeoniflorin influenced by co-administration of sinomenine in unrestrained conscious rats. J. Ethnopharmaco. 99:61-67 (2005).
6. L. C. Chen, M. H. Lee, M. H. Chou, M. F. Lin, and L. L. Yang. Pharmacokinetic study of paeoniflorin in mice after oral administration of Paeoniae radix extract. J. Chromatogr. B. 735:33-40 (1999).
7. L. C. Chen, M. H. Chou, M. F. Lin, and L. L. Yang. Pharmacokinetics of paeoniflorin after oral administration of Shao-yao Gan-cha Tang in mice. Jpn. J. Pharmacol. 88:250-255 (2002).
8. S. L. Hsiu, Y. T. Lin, K. C. Wen, Y. C. Hou, and P. D. Chao. A deglucosylated metabolite of paeoniflorin of the root of Paeonia lactiflora and its pharmacokinetics in rats. Planta Med. 69:1113-1118 (2003).
9. M. Hattori, Y. Z. Shu, M. Shimizu, T. Hayashi, N. Morita, X. G. Kobashi, and T. Namba. Metabolism of paeoniflorin and related compounds by human intestinal bacteria. Chem. Pharm. Bull. 33:3838-3846 (1985).
10. Y. Z. Shu, M. Hattori, T. Akao, K. Kobashi, K. Kagi, K. Fukuyama, T. Tsukihara, and T. Namba. Metabolism of paeoniflorin and related compounds by human intestinal bacteria. II. Structures of 7S-and 7R-paeonimetabolines I and II formed by Bacteroides fragillis and Lactobacillus brevis. Chem. Pharm. Bull. 35:2733-3726 (1987).
11. K. Chan, Z. Q. Liu, Z. H. Jiang, H. Zhou, Y. F. Wong, H. X. Xu, and L. Liu. The effects of sinomenine on intestinal absorption of paeoniflorin by everted rat gut sac model. J. Ethnopharmacol. 103:425-432 (2006).
12. Z. Tai and S. J. Hopkins. Sinomenine: antiarthritic antiinflammatory. Drugs of the Future 23:45-49 (1998).
13. L. Liu, J. Riese, K. Resch, and V. Kaever. Impairment of macrophage eicosanoid and nitric oxide production by sinomenine, an alkaloid from Sinomenium acutum. Arzneim.-Forsch. 44 (11): 1223-1226 (1994).
14. B. Vieregge, K. Resch, and V. Kaever. Synergistic effects of the alkaloid sinomenine in combination with the immunosuppressive drugs tacrolimus and mycophenolic acid. Planta Med. 44:1223-1226 (1999).
15. L. Liu, K. Resch, and V. Kaever. Inhibition of lymphocyte proliferation by the anti-rheumatic drug sinomenine. Int. J. Immunopharmacol. 16:685-691 (1996).
16. M. Hu, J. Chen, D. Tran, Y. Zhu, and G. Lenonardo. The Caco-2 cell monolayers as an intestinal metabolism model: metabolism of dipeptide Phe-Pro. J. Drug Target. 2:79-89 (1994).
17. M. Hu, J. Chen, Y. Zhu, A. H. Dantzig, R. E. Stratford, and M. T. Kuhfeld. Mechanism and kinetics of transcellular transport of a new β-lactam antibiotic loracarbef across an human intestinal epithelial model system (Caco-2). Pharm. Res.(NY) 11:1405-1413 (1994).
18. J. Chen, H. Lin, and M. Hu. Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J. Pharmacol. Exp. Ther. 304:1228-1235 (2003).
19. E. J. Jeong, X. B. Jia, and M. Hu. Disposition of formononetin via enteric recycling: metabolism and excretion in mouse intestinal perfusion and Caco-2 cell model. Mol. Pharmacol. 2:319-328 (2005).
20. E. J. Jeong, Y. Liu, H. Lin, and M. Hu. In situ single-pass perfused rat intestinal model for absorption and metabolism. In Z. Yan and G. W. Caldwell (eds.), In Methods in Pharmacology and Toxicology: Optimization in Drug Discovery - In Vitro Methods, Human, Totowa, NJ, 2004, pp. 65-76.
21. M. Hu, K. Ge, L. Roland, J. Chen, P. Tyle, and S. Roy. Determination of absorption characteristics of AG337, a novel thymidylate synthase inhibitor, using a perfused rat intestinal model. J. Pharm. Sci. 87:886-890 (1998).
22. M. Hu, P. J. Sinko, A. L. J. DeMeere, D. A. Johnson, and G. L. Amidon. Membrane permeability parameters for some amino acids and β-lactam antibiotics: application of the boundary layer approach. J. Theor. Biol. 131:107-114 (1988).
23. T. Tanaka, S. Takase, and T. Goda. A possible role of a nuclear factor NF-LPH1 in the regional expression of lactase-phlorizin hydrolase along the small intestine. J. Nutr. Sci. Vitaminol. (Tokyo) 43:565-573 (1997).
24. E. Liang, J. Proudfoot, and M. Yazdanian. Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers. Pharm. Res. 17:1168-1174 (2000).
25. Y. Liu, Y. Liu, Y. Dai, L. Y. Xun, and M. Hu. Enteric disposition and recycling of flavonoids and ginkgo flavonoids. J. Alter. Complement. Med. 9:631-640 (2003).
26. Y. Zhang, A. Gupta, H. Wang, L. Zhou, R. R. Vethanayagam, J. D. Unadkat, and Q. Mao. BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm. Res. 22: 2023-2034 (2005).
27. G. T. Ho, F. M. Moodie, and J. Satsangi. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?. Gut 52:759-766 (2003).
28. R. Tian, N. Koyabu, H. Takanaga, H. Matsuo, H. Ohtani, and Y. Sawada. Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm. Res. 19: 802-809 (2002).
29. Y. Tanaka, A. L. Slitt, T. M. Leazer, J. M. Maher, and C. D. Klaassen. Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem. Biophys. Res. Commun. 326:181-187 (2005).
30. B. M. Johnson, P. Zhang, J. D. Schuetz, and K. L. Brouwer. Characterization of transport protein expression in multidrug resistance-associated protein (mrp) 2-deficient rats. Drug Metab. Dispos. 34:556-562 (2006).